Issue 2 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

31

No.

2

January 14, 2005Jan 14, 2005

Free

DOWNLOAD THE PDF

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

Also in This 8-page Issue: NCI Seeks $6.17 Billion in “Bypass” Budget Request, But Faces Shortfall In Its Actual Budget.

NCI Names 15 to Director’s Consumer Liaison Group.

SAIC-Frederick Makes Awards To Proteomics Research Teams.

Latest State Cancer Statistics Released.

Smokers May Get Cessation Help From Medicare.

Funding Opportunities Listed.

Recent Issues

Volume 52 | Issue 24 - June 18, 2026

Volume 52 | Issue 23 - June 12, 2026

Volume 52 | Issue 22 - June 05, 2026

Volume 52 | Issue 21 - May 29, 2026

Volume 52 | Issue 20 - May 22, 2026

Volume 52 | Issue 19 - May 15, 2026